In the latest close session, Viking Therapeutics, Inc. (VKTX) was down 2.54% at $33.05. This move lagged the S&P 500's daily loss of 0.16%. Meanwhile, the Dow experienced a rise of 0.44%, and the technology-dominated Nasdaq saw a decrease of 0.76%. The company's stock has climbed by 40.79% in the past month, exceeding the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14%.Market participants will be closely following the financial results of Viking Therapeutics, Inc. in its upcoming release. The ...

In the latest trading session, Moderna (MRNA) closed at $26.25, marking a -1.83% move from the previous day. This change lagged the S&P 500's daily loss of 0.16%. At the same time, the Dow added 0.44%, and the tech-heavy Nasdaq lost 0.76%. The biotechnology company's stock has climbed by 11.98% in the past month, exceeding the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14%.The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Alnylam Pharmaceuticals (ALNY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Alnylam Pharmaceuticals is one of 956 individual stocks in the Medical sector. Collectively, ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

Group 1 - Ginkgo Bioworks Holdings, Inc. closed at $15.24, down 5.28% from the previous trading session, which is less than the S&P 500's loss of 0.28% [1] - Prior to the recent trading day, the company's shares had increased by 56.37%, significantly outperforming the Medical sector's gain of 3.31% and the S&P 500's gain of 4.03% [1] Group 2 - The upcoming earnings release is projected to show an EPS of -$1.24, reflecting a 14.81% decrease compared to the same quarter last year, with expected revenue of $39 million, down 56.2% from the prior-year quarter [2] - For the entire fiscal year, the Zacks Consensus Estimates predict an EPS of -$5.27 and revenue of $181 million, indicating changes of +49.13% and -20.28% respectively from the previous year [3] Group 3 - Recent revisions to analyst forecasts for Ginkgo Bioworks are important as they indicate changing near-term business trends, with upward revisions suggesting analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a history of outperforming, with 1 stocks returning an average annual gain of +25% since 1988; Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold) [6] Group 4 - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries, indicating strong performance potential [7]

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.62%. A quarter ago, it was expected that this company would post a loss of $0.71 per share when it actually produced a loss of $0.52, delivering a surprise of +26.76%.Over the last four quarters, the company ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Septerna, Inc. (SEPN) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 38% gain over the past four weeks.The sudden surge in the stock price likely reflects the growing investor optimism regarding the potential of Septerna’s only clinical-pipeline candidate, SEP-631, which is being developed in an early-stage study for treating chronic spontaneous urticaria and other ...